Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Merck & Co. Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Loans payable and current portion of long-term debt	1,434)	1,360)	2,649)	3,149)	3,071)	3,077)	1,372)	887)	2,839)	2,672)	1,946)	1,936)	2,979)	1,208)	2,412)	3,534)	2,488)	7,251)	6,431)	2,420)	4,718)	6,361)
Trade accounts payable	3,892)	3,784)	4,079)	3,586)	3,519)	3,514)	3,922)	3,509)	3,442)	3,680)	4,264)	3,371)	3,482)	3,715)	4,609)	3,366)	3,897)	4,034)	4,594)	3,744)	3,448)	3,572)
Accrued and other current liabilities	14,502)	12,772)	15,694)	16,539)	14,712)	14,102)	15,766)	14,840)	13,747)	13,000)	14,159)	14,222)	13,501)	14,051)	13,859)	14,214)	12,888)	11,911)	13,053)	11,690)	11,182)	10,932)
Income taxes payable	4,156)	5,181)	3,914)	4,330)	2,777)	2,398)	2,649)	1,981)	1,489)	1,872)	1,986)	1,698)	1,438)	1,571)	1,224)	954)	971)	1,490)	1,575)	984)	1,266)	1,033)
Dividends payable	2,053)	2,077)	2,084)	1,982)	1,981)	2,008)	1,985)	1,877)	1,877)	1,907)	1,884)	1,771)	1,768)	1,771)	1,768)	1,660)	1,662)	1,675)	1,674)	1,567)	1,564)	1,585)
Current liabilities	26,037)	25,174)	28,420)	29,586)	26,060)	25,099)	25,694)	23,094)	23,394)	23,131)	24,239)	22,998)	23,168)	22,316)	23,872)	23,728)	21,906)	26,361)	27,327)	20,405)	22,178)	23,483)
Long-term debt, excluding current portion	33,968)	33,484)	34,462)	34,982)	34,717)	31,142)	33,683)	33,972)	34,072)	28,074)	28,745)	28,482)	28,684)	30,586)	30,690)	22,907)	24,033)	24,002)	25,360)	26,321)	26,156)	21,637)
Deferred income taxes	1,427)	1,409)	1,387)	864)	876)	922)	871)	1,018)	996)	1,442)	1,795)	2,417)	2,974)	3,071)	3,441)	1,527)	1,489)	1,204)	1,015)	1,777)	2,091)	1,943)
Other noncurrent liabilities	7,031)	6,655)	6,465)	7,540)	7,329)	8,262)	8,792)	7,343)	7,265)	8,244)	8,323)	8,660)	8,951)	9,742)	9,434)	9,469)	9,872)	12,241)	12,482)	12,027)	12,446)	11,550)
Noncurrent liabilities	42,426)	41,548)	42,314)	43,386)	42,922)	40,326)	43,346)	42,333)	42,333)	37,760)	38,863)	39,559)	40,609)	43,399)	43,565)	33,903)	35,394)	37,447)	38,857)	40,125)	40,693)	35,130)
Total liabilities	68,463)	66,722)	70,734)	72,972)	68,982)	65,425)	69,040)	65,427)	65,727)	60,891)	63,102)	62,557)	63,777)	65,715)	67,437)	57,631)	57,300)	63,808)	66,184)	60,530)	62,871)	58,613)
Common stock, $0.50 par value	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)	1,788)
Other paid-in capital	44,644)	44,816)	44,704)	44,530)	44,362)	44,598)	44,509)	44,358)	44,219)	44,467)	44,379)	44,243)	44,115)	44,275)	44,238)	44,149)	44,039)	39,613)	39,588)	39,489)	39,373)	39,697)
Retained earnings	68,477)	66,097)	63,069)	61,384)	60,187)	56,697)	53,895)	57,082)	54,198)	62,039)	61,081)	59,928)	58,437)	56,252)	53,696)	51,691)	48,777)	48,888)	47,362)	51,107)	49,724)	48,272)
Accumulated other comprehensive loss	(5,421)	(4,965)	(4,945)	(5,371)	(5,361)	(5,274)	(5,161)	(4,916)	(4,900)	(4,883)	(4,768)	(4,743)	(4,327)	(4,369)	(4,429)	(4,590)	(4,628)	(6,622)	(6,634)	(6,383)	(6,393)	(6,391)
Treasury stock, at cost	(60,495)	(59,401)	(58,303)	(57,829)	(57,394)	(57,445)	(57,450)	(57,066)	(56,612)	(56,577)	(56,489)	(56,758)	(56,770)	(57,063)	(57,109)	(57,244)	(56,682)	(56,722)	(56,787)	(56,815)	(56,850)	(57,161)
Total Merck & Co., Inc. stockholders’ equity	48,993)	48,335)	46,313)	44,502)	43,582)	40,364)	37,581)	41,246)	38,693)	46,834)	45,991)	44,458)	43,243)	40,883)	38,184)	35,794)	33,294)	26,945)	25,317)	29,186)	27,642)	26,205)
Noncontrolling interests	67)	65)	59)	58)	66)	60)	54)	54)	49)	71)	67)	66)	75)	70)	73)	69)	94)	94)	87)	84)	102)	95)
Total equity	49,060)	48,400)	46,372)	44,560)	43,648)	40,424)	37,635)	41,300)	38,742)	46,905)	46,058)	44,524)	43,318)	40,953)	38,257)	35,863)	33,388)	27,039)	25,404)	29,270)	27,744)	26,300)
Total liabilities and equity	117,523)	115,122)	117,106)	117,532)	112,630)	105,849)	106,675)	106,727)	104,469)	107,796)	109,160)	107,081)	107,095)	106,668)	105,694)	93,494)	90,688)	90,847)	91,588)	89,800)	90,615)	84,913)

Loans payable and current portion of long-term debt: There is notable volatility in this liability category, with initial values decreasing sharply from 6361 million USD in March 2020 to 2420 million USD by September 2020, followed by oscillations throughout the subsequent quarters. The figure hits a low of 887 million USD by September 2023 before rising again to around 1400 million USD in mid-2025.
Trade accounts payable: The trade accounts payable remain relatively stable with slight fluctuations, generally oscillating between approximately 3400 and 4600 million USD without a definitive uptrend or downtrend over the observed period.
Accrued and other current liabilities: This category shows a gradually increasing trend, starting from around 10932 million USD in early 2020 to a peak near 16539 million USD by December 2023, with some moderate fluctuations particularly around early 2024.
Income taxes payable: Income taxes payable experience a steady increase overall, rising from about 1033 million USD in March 2020 to a peak exceeding 5181 million USD by March 2025, with notable spikes especially from late 2023 onwards.
Dividends payable: Dividends payable remain mostly stable, with values fluctuating narrowly between approximately 1560 million USD and 2080 million USD, suggesting consistent dividend obligations over the period.
Current liabilities: Current liabilities exhibit considerable variation, initially decreasing from about 23483 million USD in March 2020 to a low near 20405 million USD in September 2020, then rising sharply to peaks near 29586 million USD by early 2024, before a downward correction towards the end of the period.
Long-term debt, excluding current portion: Long-term debt fluctuates, initially increasing from 21637 million USD to over 30690 million USD by December 2021, followed by periods of decline mixed with rises, stabilizing near 34000 million USD towards mid-2025.
Deferred income taxes: The deferred income taxes show a downward trend overall from early values around 1943 million USD to lows near 864 million USD in late 2024, with intermittent increases and decreases throughout the quarters.
Other noncurrent liabilities: Other noncurrent liabilities trend downward, decreasing from approximately 11550 million USD in early 2020 to lows under 6500 million USD in early 2025, indicating potential liability reductions in this category.
Noncurrent liabilities: There is notable irregularity with noncurrent liabilities. They rise markedly to a peak of 43565 million USD in December 2021, then fluctuate, generally maintaining values between 40000 and 43000 million USD through 2025.
Total liabilities: Total liabilities increase overall, starting at 58613 million USD in March 2020 to a peak of nearly 73000 million USD in late 2024, with fluctuations that closely track changes in both current and noncurrent liabilities.
Common stock, $0.50 par value: Common stock remains constant at 1788 million USD throughout the entire period, indicating no changes in par value or shares issued.
Other paid-in capital: This equity component stays relatively stable with minor fluctuations around 44000 million USD, showing slight incremental changes without a clear trend.
Retained earnings: Retained earnings show an increasing trajectory overall, rising from 48272 million USD in March 2020 to nearly 68500 million USD by mid-2025, although there are intermittent dips notably around early 2023 and early 2024.
Accumulated other comprehensive loss: This account records a growing negative balance, moving from approximately -6391 million USD to just under -5800 million USD by mid-2025, with some periods of relative stability.
Treasury stock, at cost: Treasury stock values deepen over time, representing increasing cost amounts from around -57161 million USD in early 2020 to nearly -60500 million USD by mid-2025, implying continued share repurchases or retention at cost.
Total stockholders’ equity: Stockholders’ equity rises markedly from 26205 million USD in March 2020 to about 48993 million USD by mid-2025, despite a significant decline in 2023, reflecting overall net gains and possibly increased retained earnings and paid-in capital.
Noncontrolling interests: Noncontrolling interests remain minimal and fairly stable, fluctuating between approximately 49 million USD and 102 million USD with no significant trend.
Total equity: Total equity follows a similar trend to stockholders’ equity increasing from around 26300 million USD in March 2020 to nearly 49100 million USD by mid-2025, despite a dip in 2023, maintaining a stable growth pattern overall.
Total liabilities and equity: The combined figure of total liabilities and equity steadily grows from roughly 84913 million USD in March 2020 to over 117000 million USD by late 2024, indicating expansion in the company's consolidated financial position over time.

Download chart

Merck & Co. Inc. (NYSE:MRK)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data